DDX53 and cancer: No mice grew new tumours over the next month compared to 100% tumour formation in naïve mice inoculated with the same cell passage or mice with surgically removed CT26 (Fig. 6b−e), indicating OxPt/DHA plus α-PD-L1 generated long-lasting antitumour immunity to prevent cancer relapse.